Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.58 |
| ▸ | FEN1 | P39748 | 1/20 | 0.58 |
| ▸ | CES2 | O00748 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29621373 | 1.00 | ERCC5 (0.58) | ERCC5FEN1CES2CES1ALDH1A1 | |
| Bromide SCHEMBL235266 | 0.98 | ERCC5 (0.56) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL17376015 | 0.88 | ERCC5 (0.56) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL9409754 | 0.84 | PTPN1 (0.65) | CES1ALDH1A1PTPN1GSK3BMAPT | |
| SCHEMBL1199039 | 0.83 | ERCC5 (0.61) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL30547190 | 0.83 | ERCC5 (0.61) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL7863427 | 0.82 | GSK3B (0.52) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL15979733 | 0.82 | CES2 (0.62) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL29987169 | 0.82 | ERCC5 (0.74) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL5057138 | 0.82 | PTPN1 (0.50) | ERCC5FEN1CES2CES1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 621 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118834123-A | Method for preparing alpha-bromo-o-chloroacetophenone by utilizing microchannel reactor | 江苏恩华药业股份有限公司 | 2024-10-25 | — | — | CN | claimed |
| CN-105622534-A | Heterocyclic imide derivative containing bisamide structure and preparation method and application thereof | HUBEI BIOPESTICIDE ENG RES CENTER | 2016-06-01 | — | — | CN | claimed |
| JP-1013001-A | — | — | None | — | — | JP | disclosed |
| JP-7053372-A | — | — | None | — | — | JP | disclosed |
| JP-2175968-A | — | — | None | — | — | JP | disclosed |
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| US-12398151-B2 | Sumo inhibitor compounds and uses thereof | Suvalent Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4556476-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| US-20250115562-A1 | METHOD FOR PREPARING ARYL 2- TETRAZOL -1 -YI KETO WITH IMPROVED SELECTIVITY | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-04-10 | — | — | US | disclosed |
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | PRISM MEDICINES, INC. | 2025-01-09 | — | — | US | disclosed |
| US-4265898-A | ANTICOAGULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-05 | — | — | US | disclosed |
| EP-0019796-A1 | Propionic acid esters, preparation of these compounds, herbicides containing these compounds as active substances, and the use of such compounds and agents for combating weeds | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-12-10 | — | — | EP | disclosed |
| EP-0005783-A1 | Imidazo (2.1-b)-(1.3.4)-thiadiazoles, process for their preparation and their use in medicaments | BAYER AG (DE) | 1979-12-12 | — | — | EP | disclosed |
| US-4139707-A | ANTHELMINTICS | AMERICAN CYANAMID COMPANY (US) | 1979-02-13 | — | — | US | disclosed |
| US-4090025-A | ALKOXYETHYL-PHENYL-IMIDAZOLIN-2-ONES OR 2-IMIDAZOLIDONES OR IMIDAZOLIDINE-2-THIONES | AMERICAN CYANAMID COMPANY (US) | 1978-05-16 | — | — | US | disclosed |
| US-4087611-A | CHEMICAL INTERMEDIATES | AMERICAN CYANAMID COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
| US-4021485-A | BRONCHOSPASMOLYTICS, ANTIPRURITICS, ANTIALLERGICS | BOEHRINGER INGELHEIM GMBH (DT) | 1977-05-03 | — | — | US | disclosed |
| US-3965181-A | Tricyclic pharmacological agents, intermediates and methods of making | SYNTEX (U.S.A.) INC. (US) | 1976-06-22 | — | — | US | disclosed |
| JP-S06413001-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | ERCC5 3836/4885FEN1 3771/4885CES2 941/4885 |
| US-20250115562-A1 | METHOD FOR PREPARING ARYL 2- TETRAZOL -1 -YI KETO WITH IMPROVED SELECTIVITY | KARS1, KMO, KYAT1 | ERCC5 4695/4885FEN1 2743/4885CES2 3052/4885 |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | ERCC5 3142/4885FEN1 3309/4885CES2 1314/4885 |
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | ERCC5 1799/4885FEN1 1802/4885CES2 1727/4885 |
| US-12398151-B2 | Sumo inhibitor compounds and uses thereof | SUMO1, SUMO2, SUMO3 | ERCC5 730/4885FEN1 943/4885CES2 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.